(7-溴苯并[B]噻吩-2-基)甲醇 | 1171926-64-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: (7-溴苯并[B]噻吩-2-基)甲醇
• 英文名称: (7-bromobenzo[b]thiophen-2-yl)methanol
• 英文别名: (7-Bromo-1-benzothiophen-2-yl)methanol
• CAS: 1171926-64-9
• 化学式: C₉H₇BrOS
• 分子量: 243.124
• InChiKey: GOQLHIBVKJDKPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  48.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (7-溴苯并[B]噻吩-2-基)甲醇 在 四(三苯基膦)钯 、 三溴化磷 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醚 、 水 为溶剂， 反应 18.0h， 生成 ethyl 3-[2-(bromomethyl)-1-benzothiophen-7-yl]benzoate
  参考文献：
  名称：

  Discovery of the First Potent and Orally Available Agonist of the Orphan G-Protein-Coupled Receptor 52

  摘要：

  G-protein-coupled receptor 52 (GPR52) is an orphan Gs-coupled G-protein-coupled receptor. GPR52 inhibits dopamine D2 receptor signaling and activates dopamine D1/N-methyl-d-aspartate receptors via intracellular cAMP accumulation, and therefore, GPR52 agonists may have potential as a novel class of antipsychotics. A series of GPR52 agonists with a bicyclic core was designed to fix the conformation of the phenethyl ether moiety of compounds 2a and 2b. 3-[2-(3-Chloro-5-fluorobenzyl)-1-benzothiophen-7-yl]-N-(2-methoxyethyl)benzamide 7m showed potent activity (pEC50 = 7.53 ± 0.08) and good pharmacokinetic properties. Compound 7m significantly suppressed methamphetamine-induced hyperactivity in mice after oral administration of 3 mg/kg without disturbance of motor function.

  DOI：

  10.1021/jm5002919
• 作为产物：
  描述：

  7-bromobenzo[b]thiophene-2-carbaldehyde 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以15 mg的产率得到(7-溴苯并[B]噻吩-2-基)甲醇
  参考文献：
  名称：

  Metal-Free CH–CH-Type Cross-Coupling of Arenes and Alkynes Directed by a Multifunctional Sulfoxide Group

  摘要：

  A metal-free CH-CH-type coupling of arenes and alkynes, mediated by a multifunctional sulfoxide directing group, exploits nonprefunctionalized coupling partners, proceeds under mild conditions, is operationally simple, and exhibits high functional group tolerance. The products of the CH-CH coupling are highly versatile, and the metal-free process can be used for the construction and late-stage modification of important molecular scaffolds.

  DOI：

  10.1021/jacs.5b12579

文献信息

• [EN] ORAL COMPLEMENT FACTOR D INHIBITORS<br/>[FR] INHIBITEURS ORAUX DU FACTEUR D DU COMPLÉMENT
  申请人：BIOCRYST PHARM INC

  公开号：WO2021072198A1

  公开（公告）日：2021-04-15

  Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

  揭示了式(I)的化合物及其药学上可接受的盐，这些化合物是裂解系统的抑制剂。还提供了包含这种化合物的药物组合物，以及使用这些化合物和组合物治疗或预防由异常裂解系统活性特征的疾病或状况的方法。
• AMIDE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2518054A1

  公开（公告）日：2012-10-31

  A compound represented by the formula (I) wherein ring Cy1 is a 5-membered aromatic heterocycle optionally further substituted besides a group represented by -A-B, ring Cy2 is an optionally substituted benzene ring, ring Cy3 is an optionally substituted 5-membered aromatic heterocycle, ring Cy4 is an optionally substituted 6-membered aromatic ring, A is -CONRa- or -NRaCO-, Ra is a hydrogen atom or a substituent, B is a hydrogen atom or an optionally substituted C1-6 alkyl-group, X is an optionally substituted C1-2 alkylene, -Y-, -Y-CH2- or - CH2-Y-, Y is an oxygen atom, -NRb- or -S(O)m-, Rb is a hydrogen atom or a substituent, and m is 0, 1 or 2, provided that N-methyl-4-[2-[3,4,5-trimethoxyphenyl)amino]-1,3-benzoxazol-7-yl]thiophene-2-carboxamide is excluded, or a salt thereof, has an agonistic action on GPR52, and is useful as an agent for the prophylaxis or treatment of schizophrenia and the like.

  化合物的化学式为（I），其中环Cy1是一个5-成员芳香杂环，除了由-A-B表示的基团外，还可以进一步取代，环Cy2是一个可选取代的苯环，环Cy3是一个可选取代的5-成员芳香杂环，环Cy4是一个可选取代的6-成员芳香环，A是 -CONRa- 或 -NRaCO-，Ra是氢原子或取代基，B是氢原子或可选取代的C1-6烷基，X是可选取代的C1-2烷基，-Y-，-Y-CH2- 或 - CH2-Y-，Y是氧原子，-NRb- 或 -S(O)m-，Rb是氢原子或取代基，m为0、1或2，提供N-甲基-4-[2-[3,4,5-三甲氧基苯基)氨基]-1,3-苯并噁唑-7-基]噻吩-2-羧酰胺被排除，或其盐，对GPR52有激动作用，并且可用作预防或治疗精神分裂症等疾病的药物。
• Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole, a novel series of G protein-coupled receptor 52 (GPR52) agonists
  作者：Takashi Nakahata、Kazuyuki Tokumaru、Yoshiteru Ito、Naoki Ishii、Masaki Setoh、Yuji Shimizu、Toshiya Harasawa、Kazunobu Aoyama、Teruki Hamada、Masakuni Kori、Kazuyoshi Aso

  DOI：10.1016/j.bmc.2018.02.005

  日期：2018.5

  G-protein-coupled receptor 52 (GPR52) is classified as an orphan Gs-coupled G-protein-coupled receptor. GPR52 cancels dopamine D2 receptor signaling and activates dopamine D1/N-methyl-D-aspartate receptors via intracellular cAMP accumulation. Therefore, GPR52 agonists are expected to alleviate symptoms of psychotic disorders. A novel series of 1-(benzothiophen-7-yl)-1H-pyrazole as GPR52 agonists was designed and synthesized based on compound 1b. Compound 1b has been reported by our group as the first orally active GPR52 agonist, but high lipophilicity and poor aqueous solubility still remained as issues for candidate selection. To resolve these issues, replacement of the benzene ring at the 7-positon of compound 1b with heterocylic rings, such as pyrazole and pyridine, was greatly expected to reduce lipophilicity to levels for which calculated logD values were lower than that of compound 1b. While evaluating the pyrazole derivatives, introduction of a methyl substituent at the 3-position of the pyrazole ring led to increased GPR52 agonistic activity. Moreover, additional methyl substituent at the 5-position of the pyrazole and further introduction of hydroxy group to lower logD led to significant improvement of solubility while maintaining the activity. As a result, we identified 3-methyl-5-hydroxymethyl-1H-pyrazole derivative 17 (GPR52 EC50 = 21 nM, E-max = 103%, logD = 2.21, Solubility at pH 6.8 = 21 mu g/mL) with potent GPR52 agonistic activity and good solubility compared to compound 1b. Furthermore, this compound 17 dose-dependently suppressed methamphetamine-induced hyperlocomotion in mice. (c) 2018 Elsevier Ltd. All rights reserved.
• [EN] AMIDE COMPOUND<br/>[FR] COMPOSÉ AMIDE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010018874A1

  公开（公告）日：2010-02-18

  A compound having GPR52 agonist activity or a salt thereof is provided. The compound can be provided as a preventive / therapeutic agent for schizophrenia or the like. The compound is represented by the following formula (Ia): wherein A represents -CONR2- or -NR2CO-, R2 represents a hydrogen atom or the like, B represents a hydrogen atom or the like, a ring CyI represents a six-membered aromatic ring which may have one or more substituents in addition to a group represented by -A-B, a ring Cy2 represents a six-membered ring which may be substituted with a halogen atom or the like, a ring Cy3 represents a five- or six-membered ring which may have one or more substituents; X represents C1-2 alkylene or the like, m represents an integer of 0 to 2, and a ring Cy4 represents a six-membered aromatic ring which may have one or more substituents.
• Metal-Free CH–CH-Type Cross-Coupling of Arenes and Alkynes Directed by a Multifunctional Sulfoxide Group
  作者：José A. Fernández-Salas、Andrew J. Eberhart、David J. Procter

  DOI：10.1021/jacs.5b12579

  日期：2016.1.27

  A metal-free CH-CH-type coupling of arenes and alkynes, mediated by a multifunctional sulfoxide directing group, exploits nonprefunctionalized coupling partners, proceeds under mild conditions, is operationally simple, and exhibits high functional group tolerance. The products of the CH-CH coupling are highly versatile, and the metal-free process can be used for the construction and late-stage modification of important molecular scaffolds.